{"id":"NCT00095147","sponsor":"Bristol-Myers Squibb","briefTitle":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","officialTitle":"A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2004-11-02","resultsPosted":"2011-01-21","lastUpdate":"2015-03-24"},"enrollment":431,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)","otherNames":["Orencia"]},{"type":"DRUG","name":"Infliximab (INF) + MTX, DB","otherNames":[]},{"type":"DRUG","name":"Placebo (PLA) + MTX, DB","otherNames":[]},{"type":"DRUG","name":"PLA + MTX switched to ABA+ MTX, DB","otherNames":["Orencia"]},{"type":"DRUG","name":"ABA, open-label (OL)","otherNames":["Orencia"]}],"arms":[{"label":"Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])","type":"ACTIVE_COMPARATOR"},{"label":"Infliximab + MTX (DB)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo + MTX (DB)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo + MTX switched to abatacept + MTX (DB)","type":"EXPERIMENTAL"},{"label":"Abatacept (open-label)","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.","primaryOutcome":{"measure":"DB; Adjusted Mean Change From Baseline to Day 197 in Disease Activity Score (DAS) 28 Score (Erythrocyte Sedimentation Rate [ESR]) For ABA Versus PLA (Last Observation Carried Forward [LOCF] Analysis)","timeFrame":"Baseline (Day 1), 6 months (Day 197)","effectByArm":[{"arm":"ABA + MTX [DB]","deltaMin":-2.53,"sd":0.12},{"arm":"PLA + MTX [DB]","deltaMin":-1.48,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":76,"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","Denmark","Mexico","Peru","Poland","Puerto Rico","Russia","South Africa","South Korea","Spain","Sweden","Switzerland"]},"refs":{"pmids":["18055472"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":156},"commonTop":["HEADACHE","NASOPHARYNGITIS","URINARY TRACT INFECTION","DIARRHOEA","UPPER RESPIRATORY TRACT INFECTION"]}}